A Randomized Controlled Trial of Filgrastim as an Adjunct to Antibiotics for Treatment of Hospitalized Patients with Community‐Acquired Pneumonia
| Autor: | Steven M. Belknap, Stephen Farkas, Ben DeBoisblanc, Richard K. Root, Nick Fotheringham, Richard W. Carlson, Hoi Ho, Steve Nelson, Thomas J. Marrie, H. Movahhed, John W Wilson, David C. Dale |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
medicine.medical_specialty
Respiratory distress business.industry Filgrastim medicine.disease Granulocyte colony-stimulating factor law.invention Pneumonia Infectious Diseases Community-acquired pneumonia Randomized controlled trial law Internal medicine Multicenter trial Immunology and Allergy Medicine Adverse effect business Intensive care medicine medicine.drug |
| Zdroj: | Scopus-Elsevier |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1086/515694 |
| Popis: | Because of the critical role of neutrophils in host defenses, it was hypothesized that stimulation of neutrophil production and function with Filgrastim would improve the outcome of hospitalized patients with community-acquired pneumonia. To test this hypothesis, a randomized, placebo-controlled, multicenter trial of Filgrastim (300 micrograms/day up to 10 days) as an adjunct to antibiotics was conducted for these patients. Outcome measures included time to resolution of morbidity (TRM, a composite measure of temperature, respiratory rate, blood oxygenation, and chest radiograph), 28-day mortality, length of stay, and adverse events. Filgrastim increased blood neutrophils 3-fold, but TRM, mortality, and length of hospitalization were not affected. Treatment, however, accelerated radiologic improvement and appeared to reduce serious complications (e.g., empyema, adult respiratory distress syndrome, and disseminated intravascular coagulation). Filgrastim administration was safe and well tolerated in these patients. Additional trials are needed to establish the value of this approach to treatment of infectious diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|